Table 2 Clinical findings of patients underwent ASCT
From: The miRNA 196a2 rs11614913 variant has prognostic impact on Turkish patients with multiple myeloma
Patients | Controls | |||
|---|---|---|---|---|
N:156 (%) | N:200 (%) | |||
Age | 55 (28–72) | 53 (22–68) | ||
Gender | Female/Male | 75/81 (48/52) | 99/101 (50/50) | |
Diagnosis agea (years) | 55 (28–72) | |||
Ig subtypes | κ/λ | 88/40 (68/32) | ||
G/A | 84/20 (66/16) | |||
Light chain | 24 (18) | |||
Stage (Salmon-Durie) | II/III | 53/89 (38/62) | ||
A/B | 97/31 (76/24) | |||
ISS | I | 42 (33) | ||
II/III | 35/52 (28/41) | |||
ECOG | >1 | 12/127 (9.4) | ||
Hemoglobin | gr/dL | 10.4 (6.2–15) | ||
White blood cell count | /μL | 6980 (2700–18,500) | ||
Platelet count | 103/μl | 162 (61–406) | ||
C-reactive protein | mg/dl | 7.4 (2.1–352) | ||
LDH | IU/l | 208 (93-1037) | ||
β2-microglobulin | mg/l | 4.9 (1.5–47) | ||
Albumin | g/l | 3.5 (1.6–5.1) | ||
Treatment | VCd, AHSCT, Rd | 156 (100) | ||
OS (5 years) % | 79 | |||
PFSa | 55.3 | |||
Mortality | 25 (16) | |||
Follow-up period a(month) | 36 (7.8-155) | |||